The putative use of α-1-acid glycoprotein as a non-invasive marker of fibrosis
✍ Scribed by Paul Mooney; Peter Hayes; Kevin Smith
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 131 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0269-3879
- DOI
- 10.1002/bmc.704
No coin nor oath required. For personal study only.
✦ Synopsis
The acute phase response to injury or infection results in alterations in the expression of the plasma proteins produced by the liver. Many of these biomolecules are glycosylated with oligosaccharide chains covalently attached to the polypeptide backbone and the extent and composition of this glycosyaltion can be altered in a disease-dependent manner. Of particular interest is the observation that the acute phase glycoprotein, α-1-acid glycoprotein (AGP) has altered glycosylation in several physiological and pathological conditions. It is posited that changes induced in liver diseases may reflect disease severity and may therefore act as a non-invasive marker of fibrosis. This study has investigated the glycosylation of AGP in the plasma of people with varying degrees of cirrhosis and fibrosis. Hyperfucosylation was observed in all disease samples in comparison to normal plasma and was significantly increased in cirrhosis. Both sialic acid and N-acetylgalactosamine (GalNAc) were negatively associated with fibrosis. Two samples were found to express GalNAc, which as a constituent of the glycosylation of serum proteins is rare. In conclusion, fucose, sialic acid and other aspects of the glycosylation of AGP are influenced by the degree of fibrosis and as such may prove a valuable prognostic indicator of the development of cirrhosis.
📜 SIMILAR VOLUMES